Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 6
Submit an article Journal homepage
776
Views
14
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Safety and efficacy of different lenalidomide starting doses in patients with relapsed or refractory chronic lymphocytic leukemia: results of an international multicenter double-blinded randomized phase II trial*

Clemens M. WendtnerKlinikum Schwabing, Academic Teaching Hospital of University of Munich, Munich, Germany; ;Department I of Internal Medicine, University of Cologne, Cologne, Germany; Correspondence[email protected]
,
Michael HallekDepartment I of Internal Medicine, University of Cologne, Cologne, Germany; ;Cologne Cluster of Excellence in Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany;
,
Graeme A. M. FraserJuravinski Cancer Centre, McMaster University, Hamilton, Ontario, Canada;
,
Anne-Sophie MichalletHospices Civils De Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, Lyon, France;
,
Peter HillmenSt James’s Institute of Oncology, Leeds, UK;
,
Jan DürigUniversity Hospital Essen, Essen, Germany;
,
Matt KalaycioCleveland Clinic, Cleveland, OH, USA;
,
John G. GribbenBarts Cancer Institute, Queen Mary, University of London, London, UK;
,
Stephan StilgenbauerDepartment of Internal Medicine III, Ulm University, Ulm, Germany;
,
Andreas BuhlerDepartment of Internal Medicine III, Ulm University, Ulm, Germany;
,
Thomas J. KippsUniversity of California San Diego Moores Cancer Center, La Jolla, CA, USA;
,
Brendan PurseCelgene Corporation, Summit, NJ, USA;
,
Jennie ZhangCelgene Corporation, Summit, NJ, USA;
,
Sabine De BedoutCelgene Corporation, Boudry, Switzerland;
,
Jay MeiCelgene Corporation, Summit, NJ, USA;
&
Asher Chanan-KhanMayo Clinic, Jacksonville, FL, USACorrespondence[email protected]
 show all
Pages 1291-1299 | Received 07 Jul 2015, Accepted 28 Nov 2015, Published online: 14 Jan 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Marc Sorigue, Elisa Orna & Juan-Manuel Sancho. (2018) Venous thromboembolism in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia treated with lenalidomide: a systematic review. Leukemia & Lymphoma 59:11, pages 2602-2611.
Read now
Satyen Harish Gohil, Nicola Maciocia, Pip Patrick, Thomas Roberts, Nicholas Counsell, Paul Smith, Laura Clifton-Hadley, Kate Cwynarski, Andrew Pettitt & Amit Chunilal Nathwani. (2018) LenD: a study to establish the safety and efficacy of lenalidomide and dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia. Leukemia & Lymphoma 59:7, pages 1730-1733.
Read now
Rossana Maffei, Stefania Fiorcari, Silvia Martinelli, Stefania Benatti, Jenny Bulgarelli, Lara Rizzotto, Giulia Debbia, Rita Santachiara, Gian Matteo Rigolin, Francesco Forconi, Davide Rossi, Luca Laurenti, Giuseppe A. Palumbo, Daniele Vallisa, Antonio Cuneo, Gianluca Gaidano, Mario Luppi & Roberto Marasca. (2018) Increased SHISA3 expression characterizes chronic lymphocytic leukemia patients sensitive to lenalidomide. Leukemia & Lymphoma 59:2, pages 423-433.
Read now
Gilad Itchaki & Jennifer R. Brown. (2017) Lenalidomide in the treatment of chronic lymphocytic leukemia. Expert Opinion on Investigational Drugs 26:5, pages 633-650.
Read now
Constantine S. Tam & Aaron Polliack. (2016) Defining the appropriate starting dose of lenalidomide in chronic lymphocytic leukemia: remember the old fable of the hare and the tortoise. Leukemia & Lymphoma 57:6, pages 1247-1248.
Read now

Articles from other publishers (9)

Nikolaos Ioannou, Khushi Jain & Alan G. Ramsay. (2021) Immunomodulatory Drugs for the Treatment of B Cell Malignancies. International Journal of Molecular Sciences 22:16, pages 8572.
Crossref
Valentina Griggio, Francesca Perutelli, Chiara Salvetti, Elia Boccellato, Mario Boccadoro, Candida Vitale & Marta Coscia. (2020) Immune Dysfunctions and Immune-Based Therapeutic Interventions in Chronic Lymphocytic Leukemia. Frontiers in Immunology 11.
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Alexander Egle, Lisa Pleyer, Thomas Melchardt, Tanja Nicole Hartmann & Richard Greil. (2018) Remission maintenance treatment options in chronic lymphocytic leukemia. Cancer Treatment Reviews 70, pages 56-66.
Crossref
V. VENTURI, T. MASEK & M. POSPISEK. (2018) A Blood Pact: the Significance and Implications of eIF4E on Lymphocytic Leukemia. Physiological Research, pages 363-382.
Crossref
Bruce D. Cheson, Sari Heitner Enschede, Elisa Cerri, Monali Desai, Jalaja Potluri, Nicole Lamanna & Constantine Tam. (2017) Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia with Novel Targeted Agents. The Oncologist 22:11, pages 1283-1291.
Crossref
Maria Winqvist, Fariba Mozaffari, Marzia Palma, Sandra Eketorp Sylvan, Lotta Hansson, Håkan Mellstedt, Anders Österborg & Jeanette Lundin. (2016) Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. Cancer Immunology, Immunotherapy 66:1, pages 91-102.
Crossref
Francesca Arruga & Silvia Deaglio. 2018. Mechanisms of Drug Resistance in Cancer Therapy. Mechanisms of Drug Resistance in Cancer Therapy 203 229 .
A Bühler, C-M Wendtner, T J Kipps, L Rassenti, G A M Fraser, A-S Michallet, P Hillmen, J Dürig, S A Gregory, M Kalaycio, T Aurran-Schleinitz, L Trentin, J G Gribben, A Chanan-Khan, B Purse, J Zhang, S De Bedout, J Mei, M Hallek & S Stilgenbauer. (2016) Lenalidomide treatment and prognostic markers in relapsed or refractory chronic lymphocytic leukemia: data from the prospective, multicenter phase-II CLL-009 trial. Blood Cancer Journal 6:3, pages e404-e404.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.